1. Male or Female aged 18 to 79 years (both inclusive) a. Phase I: Subjects aged 18 to 45 years (both inclusive) b. Phase II: Subjects aged 18 to 79 years (both inclusive) 2. Healthy participants as determined by medical history, physical examination, vital signs and clinical laboratory examination with no clinically significant deviations as judged by the Investigator at screening and randomization (Day 0) 3. Test negative for SARS-CoV-2 infection by RT-PCR test at screening 4. Test negative for SARS-CoV-2 IgG antibody presence at screening 5. Capable and willing to provide written informed consent prior to the performance of any study-specific procedures

1. Male or Female aged 18 to 79 years (both inclusive) a. Phase I: Subjects aged 18 to 45 years (both inclusive) b. Phase II: Subjects aged 18 to 79 years (both inclusive) 2. Healthy participants as determined by medical history, physical examination, vital signs and clinical laboratory examination with no clinically significant deviations as judged by the Investigator at screening and randomization (Day 0) 3. Test negative for SARS-CoV-2 infection by RT-PCR test at screening 4. Test negative for SARS-CoV-2 IgG antibody presence at screening 5. Capable and willing to provide written informed consent prior to the performance of any study-specific procedures